Reijs Babette L R, Teunissen Charlotte E, Goncharenko Nikolai, Betsou Fay, Blennow Kaj, Baldeiras Inês, Brosseron Frederic, Cavedo Enrica, Fladby Tormod, Froelich Lutz, Gabryelewicz Tomasz, Gurvit Hakan, Kapaki Elisabeth, Koson Peter, Kulic Luka, Lehmann Sylvain, Lewczuk Piotr, Lleó Alberto, Maetzler Walter, de Mendonça Alexandre, Miller Anne-Marie, Molinuevo José L, Mollenhauer Brit, Parnetti Lucilla, Rot Uros, Schneider Anja, Simonsen Anja Hviid, Tagliavini Fabrizio, Tsolaki Magda, Verbeek Marcel M, Verhey Frans R J, Zboch Marzena, Winblad Bengt, Scheltens Philip, Zetterberg Henrik, Visser Pieter Jelle
Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht University Medical Center , Maastricht , Netherlands.
Neurochemistry Laboratory and Biobank, Department of Clinical Chemistry, VU University Medical Center , Amsterdam , Netherlands.
Front Neurol. 2015 Oct 15;6:216. doi: 10.3389/fneur.2015.00216. eCollection 2015.
Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.
生物样本库是生物标志物发现和检测方法开发的重要资源。阿尔茨海默病和帕金森病生物标志物（BIOMARKAPD）是一项欧洲多中心研究，由欧盟联合计划——神经退行性疾病研究资助，旨在改善体液标志物在阿尔茨海默病（AD）和帕金森病（PD）诊断及预后方面的临床应用。其目标是规范现有检测方法的评估，并验证用于AD和PD的新型体液生物标志物。为支持新型生物标志物和检测方法的验证，已建立了一个针对神经退行性疾病患者的体液及相关数据的中央生物样本库和一个虚拟生物样本库。在中央生物样本库中，脑脊液（CSF）和血液样本按照BIOMARKAPD标准化的分析前程序收集，并存储于卢森堡综合生物样本库。虚拟生物样本库提供了每个站点可用的CSF、血浆、血清和DNA样本的概述。目前，在BIOMARKAPD的中央生物样本库中，有来自400多名认知正常、轻度认知障碍（MCI）、AD、额颞叶痴呆（FTD）、血管性痴呆、多系统萎缩、进行性核上性麻痹、PD伴痴呆、路易体痴呆患者的样本。虚拟生物样本库包含来自21个地方生物样本库的8600多名诊断各异的受试者的信息。已推出一个网站，以便从中央生物样本库和虚拟生物样本库请求样本。
